Increased live birth rates with gnrh agonist addition for luteal support in ICSI/IVF cycles: A systematic review and meta-analysis

Human Reproduction Update

Volumn 17, Issue 6, 2011, Pages 734-740

  Kyrou, D ^a   Kolibianakis, E M ^a   Fatemi, H M ^b   Tarlatzi, T B ^a   Devroey, P ^b   Tarlatzis, B C ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

Gnrh agonist; ICSI IVF; Live birth; Luteal support

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; DYDROGESTERONE; GANIRELIX; GONADORELIN AGONIST; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; TRIPTORELIN;

ARTICLE; BIRTH RATE; EMBRYO TRANSFER; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; LUTEAL PHASE; META ANALYSIS; MULTIPLE PREGNANCY; OOCYTE CLEAVAGE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

CORPUS LUTEUM MAINTENANCE; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFANT, NEWBORN; LIVE BIRTH; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 80054680525     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmr029     Document Type: Article

References (27)

1. Ata B, Urman B. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?. Reprod Biomed Online 2010;20:165-166.
2. Ata B, Yakin K, Balaban B, Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum Reprod 2008;23:668-673.
3. Chardonnens D, Sylvan K, Walker D, Bischof P, Sakkas D, Campana A. Triptorelin acetate administration in early pregnancy: case reports and review of the literature. Eur J Obstet Gynecol Reprod 1998;80:143-149.
4. Daya S, Gunby JL. WITHDRAWN: luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2008;16 CD004830.
5. Elefant E, Biour B, Blumberg-Tick J, Roux C, Thomas F. Administration of a GnRH agonist during pregnancy: follow-up of 28 pregnancies exposed to triptorelin. Fertil Steril 1995;63:1111-1113.
6. Evers JL. Publication bias in reproductive research. Hum Reprod 2000; 15:2063-2066.
7. Fujii S, Sato S, Fukui A, Kimura H, Kasai G, Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod 2001;16:1671-1675.
8. Gartner B, Moreno C, Marinaro A, Remohi J, Simon C, Pellicer A. Accidental exposure to daily long-acting gonadotrophin-releasing hormone analogue administration and pregnancy in an in-vitro fertilization cycle. Hum Reprod 1997;12:2557-2559.
9. Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E. Impaired corpus luteum and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod 1992;7:465-468.
10. Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, Vicdan K. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online 2009;19:472-477.
11. Isikoglu M, Ozgur K, Oehninger S. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. J Reprod Med 2007;52:639-644.
12. Lahat E, Raziel A, Friedler S, Schieber-Kazir M, Ron-El R. Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy. Hum Reprod 1998;14:2656-2660.
13. Papanikolaou EG, Platteau P, Albano C, Kolibianakis E, Devroey P. Achievement of pregnancy three times in the same patient during luteal GnRH agonist administration. Reprod Biomed Online 2005;10:347-349.
14. Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 2005;20:1798-1804.
15. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006; 21:1894-1900.
16. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002;17:2287-2299.
17. Raga F, Casañ EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998;59:661-669.
18. Raga F, Casañ EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 1999;140:3705-3712.
19. Razieh DF, Maryam AR, Nasim T. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection. Taiwan J Obstet Gynecol 2009;48: 245-248.
20. Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990;70:421-430.
21. Ron-El R, Golan A, Herman A, Raziel A, Soffer Y, Caspi E. Midluteal gonadotropin-releasing hormone analog administration in early pregnancy. Fertil Steril 1990;53:572-574.
22. Smitz J, Camus M, Devroey P, Bollen N, Tournaye H, Van Steirteghem AC. The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 1991;6:290-293.
23. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001; 16:663-667.
24. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004;19:1176-1180.
25. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006;21:2572-2579.
26. Wilshire GB, Emmi AM, Gagliardi CC, Weiss G. GnRH agonist administration in early human pregnancy is associated with normal outcomes. Fertil Steril 1993; 60:980-983.
27. Young DC, Snabes MC, Poindexter AN. GnRH agonist exposure during the first trimester of pregnancy. Obstet Gynecol 1993;81:587-589.